Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioAtla, Inc.
  6. News
  7. Summary
    BCAB   US09077B1044

BIOATLA, INC.

(BCAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioAtla, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021

08/13/2021 | 05:54pm EDT

BioAtla, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported collaboration revenue of $250,000 compared to $190,000 a year ago. Loss from operations was $30,460,000 compared to $4,520,000 a year ago. Consolidated net loss and comprehensive loss was $30,381,000 compared to $6,222,000 a year ago. For the six months, the company reported collaboration revenue of $250,000 compared to $279,000 a year ago. Loss from operations was $49,257,000 compared to $5,629,000 a year ago. Consolidated net loss and comprehensive loss was $49,082,000 compared to $7,826,000 a year ago.


ę S&P Capital IQ 2021
All news about BIOATLA, INC.
09/29BIOATLA : to Conduct $75 Million Private Placement of Common Stock
MT
09/29BIOATLA : ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES (Form 8-K)
PU
09/29BIOATLA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se..
AQ
09/29BIOATLA : Announces Private Placement of 2.7 Million Shares
PR
09/28BioAtla, Inc. announced that it expects to receive $75.0008 million in funding from a g..
CI
08/18BIOATLA : JPMorgan Adjusts BioAtla's Price Target to $64 from $62, Keeps Overweight Rating
MT
08/16BIOATLA : Posts Wider Q2 Loss
MT
08/13BIOATLA : Announces Second Quarter 2021 Financial Results And Provides Clinical Update
PR
08/13BioAtla, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter an..
CI
08/13BIOATLA : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
More news
Analyst Recommendations on BIOATLA, INC.
More recommendations
Financials (USD)
Sales 2021 17,6 M - -
Net income 2021 -95,2 M - -
Net cash 2021 186 M - -
P/E ratio 2021 -10,1x
Yield 2021 -
Capitalization 958 M 958 M -
EV / Sales 2021 43,8x
EV / Sales 2022 81,8x
Nbr of Employees 36
Free-Float 80,0%
Chart BIOATLA, INC.
Duration : Period :
BioAtla, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOATLA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 28,35 $
Average target price 70,00 $
Spread / Average Target 147%
EPS Revisions
Managers and Directors
Jay M. Short Chairman & Chief Executive Officer
Scott Andrew Smith President & Director
Richard A. Waldron Chief Financial Officer
Cathy Chang Vice President-Research & Development
Eric Sievers Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOATLA, INC.-16.64%958
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414